ArticleAnnals of hematology2026
The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To investigate the clinical characteristics and prognosis of acute B-cell lymphoblastic leukemia (B-ALL) patients with MEF2D fusions. We retrospectively analyzed 15 newly diagnosed MEF2D-positive B-ALL patients admitted to The First Affiliated Hospital of Soochow University between January 2021 and December 2024, confirmed via targeted RNA sequencing (RNA-seq) or reverse transcription multiplex PCR. Immunophenotypic, cytogenetic, and molecular mutation profiles were assessed, along with treatment responses. Among the 228 patients initially diagnosed with high-risk B-ALL, 15 patients (6.58%) were positive for the MEF2D fusions. Of these positive cases, extramedullary infiltration was observed in 5 cases, with co-occurring mutations including KRAS (n = 6) and NRAS (n = 4); 4 patients had complex karyotypes. The MEF2D-positive group exhibited significantly inferior overall survival (OS) (P < 0.001) and event-free survival (EFS) (P < 0.001) compared to the MEF2D-negative cohort. After induction therapy, 13 patients achieved complete remission (CR), while 2 with partial response (PR) attained CR following venetoclax (VEN)-combined reinduction. Thirteen patients received immunotherapy, with 9 bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Moreover, one patient proceeded directly to allo-HSCT post-chemotherapy CR. The OS was significantly higher in the transplantation group compared to the non-transplantation group (P < 0.001), but there was no statistical difference between the two groups according to allo-HSCT as a time-dependent variable (P = 0.36). Case 12 achieved negativity for MEF2D with Chidamide incorporated into the preconditioning regimen. Case 3 experienced early post-transplant relapse but achieved transient remission after Ven-combined treatment. At the last follow-up, 10 patients (66.7%) relapsed and 10 patients (66.7%) died each, with a median OS of 14 (5–34)months. B-ALL with MEF2D fusions frequently demonstrates multilineage involvement, poor response to conventional chemotherapy, and extramedullary infiltration. Incorporating venetoclax and the histone deacetylase inhibitor chidamide into induction, salvage, or preconditioning regimens may probably improve outcomes for MEF2D-positive patients, though certainly required further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.